Tag Archives: Strategy
Alliance Management is Being Neglected, Says Study
Survey finds disconnect between perceived importance of alliance management function at C-level and actual commitment to it.
The Rhythm of Business has released the results of a recent study titled The Practice of Alliance Management in the Biopharmaceutical Industry that examines the state of alliance management in pharmaceutical companies. The study, co-sponsored by the Biopharma Council [...]
Recasting Big Pharmas R&D Role: Wellcome Trust or Wal-Mart?
New research suggests it’s time industry took a radically different approach to drug development, leaving compound innovation to others while mobilizing its global scale and promotional muscle to drive timely acceptance in the marketplace.
The biggest strategic issue confronting Big Pharma today is balancing that legacy of ”big” — maintaining the capacity to invest in the [...]
MedImmune Bets Its Fate on “Biobetters”
AstraZeneca’s biologics shop makes a decisive move in the biosimilars market.
MedImmune, the biologics shop bought by AstraZeneca (AZ) for a staggering $15 billion in 2007 promising one new drug a year for the foundering British firm, has made precious little news since the deal. But all of a sudden the post-Labor Day wires were crackling [...]
Posted in Biotech, Deals, Global, R&D, Strategy Also tagged AstraZeneca, biobetters, biosimilars, Deals, MedImmune, R&D 1 Comment
How Do We Raise R&D Productivity?
That’s the big question that no one has answered yet. So perhaps its worth breaking it down into smaller parts, suggests Dr Brian D Smith.
An ill-posed question is a mathematician’s term that well describes what many Big Pharma companies are asking themselves, namely, how can we raise R&D productivity? It’s ill-posed because it has not [...]
Posted in Europe, Global, Guest Blog, Marketing, Strategy Also tagged pipeline, Productivity, R&D Leave a comment

GE Capital CFO Survey Reveals State of Pharma Industry in 2010, 2011